Objective: Diabetes mellitus may cause sexual dysfunction among men, medical complications, and psychological disturbances. This study was carried out to assess quality of life and erectile dysfunction among a sample of diabetic men. Materials: In the current study, we included 500 diabetic men attending the Andrology outpatient clinic, Diabetes outpatient clinic, diabetic foot outpatient clinic, Assiut University Hospitals, Egypt. The participants were evaluated using the Arabic version of the International Index of Erectile Function questionnaire and the Arabic version of SF-36 questionnaire. Results: The mean age was 53.13 ± 11.92 years. Of the 500 participants, erectile dysfunction was severe in 112 patients (22.4%), moderate in 82 patients (16.4%), mild-to-moderate in 116 patients (23.2%), mild in 158 patients (31.6%), and 32 patients (6.4%) had no impairment. Erectile dysfunction increased with age of participants, smoking, and duration of diabetes. Conclusion: Lifestyle changes and clinical management of accompanying medical complications with better understanding of the psychological problems that face diabetic people with erectile dysfunction can lead to better management and reduction of the incidence of erectile dysfunction.

Objective: Diabetes mellitus may cause sexual dysfunction among men, medical complications, and psychological disturbances. This study was carried out to assess quality of life and erectile dysfunction among a sample of diabetic men. Materials: In the current study, we included 500 diabetic men attending the Andrology outpatient clinic, Diabetes outpatient clinic, diabetic foot outpatient clinic, Assiut University Hospitals, Egypt. The participants were evaluated using the Arabic version of the International Index of Erectile Function questionnaire and the Arabic version of SF-36 questionnaire. Results: The mean age was 53.13 ± 11.92 years. Of the 500 participants, erectile dysfunction was severe in 112 patients (22.4%), moderate in 82 patients (16.4%), mild-to-moderate in 116 patients (23.2%), mild in 158 patients (31.6%), and 32 patients (6.4%) had no impairment. Erectile dysfunction increased with age of participants, smoking, and duration of diabetes. Conclusion: Lifestyle changes and clinical management of accompanying medical complications with better understanding of the psychological problems that face diabetic people with erectile dysfunction can lead to better management and reduction of the incidence of erectile dysfunction.

Objective: Premature ejaculation (PE) is one of the most common sexual dysfunctions among men. This study was carried out to assess the quality of life and the on-demand effect of two selective serotonin reuptake inhibitors (dapoxetine and sertraline) on vaginal latency and coital frequency in a sample of Egyptian men complaining of PE. Patients and methods: In the current study we included 64 men attending Andrology Outpatient Clinic, Assiut University Hospitals, Egypt. These participants were evaluated using the Arabic Index of PE questionnaire, measuring the intravaginal ejaculation latency time (IELT) time and coital frequency before and after therapy. Results: The mean age was 34.81±7.19 years in the dapoxetine group and 37.47±7.22 years in the sertraline group. The mean IELT in the dapoxetine group was 0.71±0.16 min before therapy, and it increased significantly to 2.51±0.11 min after therapy (P=0.001). The mean IELT for the sertraline group before therapy was 0.65±0.15 min, and it increased significantly to 2.61±0.11 min (P=0.001). Significant correlations were found between Arabic Index Premature Ejaculation (AIPE) scores and coital frequency before and after treatment in both groups. Conclusion: Patients with severe PE showed mild-to-moderate improvement in IELT and AIPE. Both groups showed improvement in IELT and AIPE scores. The sertraline group was better compared with the dapoxetine group as regards ejaculation latency, ejaculation control, and patient satisfaction.

Objective: Premature ejaculation (PE) is one of the most common sexual dysfunctions among men. This study was carried out to assess the quality of life and the on-demand effect of two selective serotonin reuptake inhibitors (dapoxetine and sertraline) on vaginal latency and coital frequency in a sample of Egyptian men complaining of PE. Patients and methods: In the current study we included 64 men attending Andrology Outpatient Clinic, Assiut University Hospitals, Egypt. These participants were evaluated using the Arabic Index of PE questionnaire, measuring the intravaginal ejaculation latency time (IELT) time and coital frequency before and after therapy. Results: The mean age was 34.81±7.19 years in the dapoxetine group and 37.47±7.22 years in the sertraline group. The mean IELT in the dapoxetine group was 0.71±0.16 min before therapy, and it increased significantly to 2.51±0.11 min after therapy (P=0.001). The mean IELT for the sertraline group before therapy was 0.65±0.15 min, and it increased significantly to 2.61±0.11 min (P=0.001). Significant correlations were found between Arabic Index Premature Ejaculation (AIPE) scores and coital frequency before and after treatment in both groups. Conclusion: Patients with severe PE showed mild-to-moderate improvement in IELT and AIPE. Both groups showed improvement in IELT and AIPE scores. The sertraline group was better compared with the dapoxetine group as regards ejaculation latency, ejaculation control, and patient satisfaction.

Background and study aim Concomitant hepatitis C virus (HCV) infection and psoriasis vulgaris (PV) are not uncommon coexisting diseases, especially in areas with high viral hepatitis endemicity. To date, data about the interaction between both diseases are scarce. Therefore, we aimed to describe the possible interplay between the HCV viral load and psoriatic activity in concomitant Egyptian diseased patients. Patients and methods Between December 2011 and August 2013, all psoriatic patients attending Assiut University Hospital outpatient clinics were tested for HCV serologic assay. Patients with positively coexisting diseases were further reevaluated for psoriasis area severity index (PASI) score assessment, liver function tests, HCV-RNA-polymerase chain reaction (PCR) assays, and sonographic examination of the liver. For comparative purposes, another matched group (n = 26) with psoriasis only (HCV-negative group) was enrolled as a control. Results During the period of the study, 20 patients with concomitant PV and HCV infection (HCV-positive group; 50% males, mean age of 44.15 ± 10.66 years) were recruited. The mean PASI score was 44.75 ± 10.38 and clinical signs of liver dysfunction were observed in 40% (n = 8), 100% had abnormal liver function tests (n = 20), and 75% had sonographic findings of cirrhosis (n = 15). The PASI score was significantly higher in the HCV-positive psoriatic group compared to the HCV-negative control (p 0.001). Significant correlations were detected between the PASI score and the viral loads, and also with alanine aminotransferase (ALT). Conclusion When HCV was found concomitantly with PV, a high possibility of severe disease pattern will be expected that entails special precautions in the treatment process.

Background and study aim Concomitant hepatitis C virus (HCV) infection and psoriasis vulgaris (PV) are not uncommon coexisting diseases, especially in areas with high viral hepatitis endemicity. To date, data about the interaction between both diseases are scarce. Therefore, we aimed to describe the possible interplay between the HCV viral load and psoriatic activity in concomitant Egyptian diseased patients. Patients and methods Between December 2011 and August 2013, all psoriatic patients attending Assiut University Hospital outpatient clinics were tested for HCV serologic assay. Patients with positively coexisting diseases were further reevaluated for psoriasis area severity index (PASI) score assessment, liver function tests, HCV-RNA-polymerase chain reaction (PCR) assays, and sonographic examination of the liver. For comparative purposes, another matched group (n = 26) with psoriasis only (HCV-negative group) was enrolled as a control. Results During the period of the study, 20 patients with concomitant PV and HCV infection (HCV-positive group; 50% males, mean age of 44.15 ± 10.66 years) were recruited. The mean PASI score was 44.75 ± 10.38 and clinical signs of liver dysfunction were observed in 40% (n = 8), 100% had abnormal liver function tests (n = 20), and 75% had sonographic findings of cirrhosis (n = 15). The PASI score was significantly higher in the HCV-positive psoriatic group compared to the HCV-negative control (p 0.001). Significant correlations were detected between the PASI score and the viral loads, and also with alanine aminotransferase (ALT). Conclusion When HCV was found concomitantly with PV, a high possibility of severe disease pattern will be expected that entails special precautions in the treatment process.

Background and study aim Concomitant hepatitis C virus (HCV) infection and psoriasis vulgaris (PV) are not uncommon coexisting diseases, especially in areas with high viral hepatitis endemicity. To date, data about the interaction between both diseases are scarce. Therefore, we aimed to describe the possible interplay between the HCV viral load and psoriatic activity in concomitant Egyptian diseased patients. Patients and methods Between December 2011 and August 2013, all psoriatic patients attending Assiut University Hospital outpatient clinics were tested for HCV serologic assay. Patients with positively coexisting diseases were further reevaluated for psoriasis area severity index (PASI) score assessment, liver function tests, HCV-RNA-polymerase chain reaction (PCR) assays, and sonographic examination of the liver. For comparative purposes, another matched group (n = 26) with psoriasis only (HCV-negative group) was enrolled as a control. Results During the period of the study, 20 patients with concomitant PV and HCV infection (HCV-positive group; 50% males, mean age of 44.15 ± 10.66 years) were recruited. The mean PASI score was 44.75 ± 10.38 and clinical signs of liver dysfunction were observed in 40% (n = 8), 100% had abnormal liver function tests (n = 20), and 75% had sonographic findings of cirrhosis (n = 15). The PASI score was significantly higher in the HCV-positive psoriatic group compared to the HCV-negative control (p 0.001). Significant correlations were detected between the PASI score and the viral loads, and also with alanine aminotransferase (ALT). Conclusion When HCV was found concomitantly with PV, a high possibility of severe disease pattern will be expected that entails special precautions in the treatment process.

Background and study aim Concomitant hepatitis C virus (HCV) infection and psoriasis vulgaris (PV) are not uncommon coexisting diseases, especially in areas with high viral hepatitis endemicity. To date, data about the interaction between both diseases are scarce. Therefore, we aimed to describe the possible interplay between the HCV viral load and psoriatic activity in concomitant Egyptian diseased patients. Patients and methods Between December 2011 and August 2013, all psoriatic patients attending Assiut University Hospital outpatient clinics were tested for HCV serologic assay. Patients with positively coexisting diseases were further reevaluated for psoriasis area severity index (PASI) score assessment, liver function tests, HCV-RNA-polymerase chain reaction (PCR) assays, and sonographic examination of the liver. For comparative purposes, another matched group (n = 26) with psoriasis only (HCV-negative group) was enrolled as a control. Results During the period of the study, 20 patients with concomitant PV and HCV infection (HCV-positive group; 50% males, mean age of 44.15 ± 10.66 years) were recruited. The mean PASI score was 44.75 ± 10.38 and clinical signs of liver dysfunction were observed in 40% (n = 8), 100% had abnormal liver function tests (n = 20), and 75% had sonographic findings of cirrhosis (n = 15). The PASI score was significantly higher in the HCV-positive psoriatic group compared to the HCV-negative control (p 0.001). Significant correlations were detected between the PASI score and the viral loads, and also with alanine aminotransferase (ALT). Conclusion When HCV was found concomitantly with PV, a high possibility of severe disease pattern will be expected that entails special precautions in the treatment process.

Background and study aim Concomitant hepatitis C virus (HCV) infection and psoriasis vulgaris (PV) are not uncommon coexisting diseases, especially in areas with high viral hepatitis endemicity. To date, data about the interaction between both diseases are scarce. Therefore, we aimed to describe the possible interplay between the HCV viral load and psoriatic activity in concomitant Egyptian diseased patients. Patients and methods Between December 2011 and August 2013, all psoriatic patients attending Assiut University Hospital outpatient clinics were tested for HCV serologic assay. Patients with positively coexisting diseases were further reevaluated for psoriasis area severity index (PASI) score assessment, liver function tests, HCV-RNA-polymerase chain reaction (PCR) assays, and sonographic examination of the liver. For comparative purposes, another matched group (n = 26) with psoriasis only (HCV-negative group) was enrolled as a control. Results During the period of the study, 20 patients with concomitant PV and HCV infection (HCV-positive group; 50% males, mean age of 44.15 ± 10.66 years) were recruited. The mean PASI score was 44.75 ± 10.38 and clinical signs of liver dysfunction were observed in 40% (n = 8), 100% had abnormal liver function tests (n = 20), and 75% had sonographic findings of cirrhosis (n = 15). The PASI score was significantly higher in the HCV-positive psoriatic group compared to the HCV-negative control (p 0.001). Significant correlations were detected between the PASI score and the viral loads, and also with alanine aminotransferase (ALT). Conclusion When HCV was found concomitantly with PV, a high possibility of severe disease pattern will be expected that entails special precautions in the treatment process.

Background and study aim Concomitant hepatitis C virus (HCV) infection and psoriasis vulgaris (PV) are not uncommon coexisting diseases, especially in areas with high viral hepatitis endemicity. To date, data about the interaction between both diseases are scarce. Therefore, we aimed to describe the possible interplay between the HCV viral load and psoriatic activity in concomitant Egyptian diseased patients. Patients and methods Between December 2011 and August 2013, all psoriatic patients attending Assiut University Hospital outpatient clinics were tested for HCV serologic assay. Patients with positively coexisting diseases were further reevaluated for psoriasis area severity index (PASI) score assessment, liver function tests, HCV-RNA-polymerase chain reaction (PCR) assays, and sonographic examination of the liver. For comparative purposes, another matched group (n = 26) with psoriasis only (HCV-negative group) was enrolled as a control. Results During the period of the study, 20 patients with concomitant PV and HCV infection (HCV-positive group; 50% males, mean age of 44.15 ± 10.66 years) were recruited. The mean PASI score was 44.75 ± 10.38 and clinical signs of liver dysfunction were observed in 40% (n = 8), 100% had abnormal liver function tests (n = 20), and 75% had sonographic findings of cirrhosis (n = 15). The PASI score was significantly higher in the HCV-positive psoriatic group compared to the HCV-negative control (p 0.001). Significant correlations were detected between the PASI score and the viral loads, and also with alanine aminotransferase (ALT). Conclusion When HCV was found concomitantly with PV, a high possibility of severe disease pattern will be expected that entails special precautions in the treatment process.